BioSpace News Archive

The company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant.

The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.

GentiBio focuses on engineered regulatory T-cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

With a $30 million investment, Versant Ventures launches Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.

According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.

Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.

Researchers are developing simpler COVID-19 diagnostic tests for use outside of labs in an effort to make mass testing available, fast and inexpensive.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

The global market for viral conjunctivitis pipeline drugs is competitive in nature and is expected to observe a substantial rise in the level of competition in the next few years, thanks to the rising number of players projected to enter the market, states a new market intelligence study by Transparency Market Research.

Transparency Market Research has published a new report titled, ‘Topical Pain Management Therapeutics in Sports Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.